Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability

High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC). Herein, we revealed that pleckstrin-2 (PLEK2) cooperated with YTHDF2 to enhance TYMS mRNA stability in CRC via an...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular life sciences : CMLS Vol. 82; no. 1; pp. 284 - 15
Main Authors: Zhou, Qian, Li, Yanxia, Li, Xiaomei, Zhang, Shujing, Wang, Ying, Li, Zhuoran, Wang, Xia, Li, Yuan, Li, Jingxin, Lu, Chunhua, Shen, Yuemao, Zhao, Baobing
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 19.07.2025
Springer Nature B.V
Springer
Subjects:
ISSN:1420-9071, 1420-682X, 1420-9071
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC). Herein, we revealed that pleckstrin-2 (PLEK2) cooperated with YTHDF2 to enhance TYMS mRNA stability in CRC via an m 6 A dependent manner . Silencing of PLEK2 led to the degradation of TYMS mRNA that suppressed DNA replication, which activated p53/p21 signaling and consequent inhibition of CRC cell proliferation via the cellular senescence. Additionally, PLEK2 is also required for CRC cell migration, invasion and stemness-like properties. PLEK2 inhibition is sufficient to ameliorate the progression of AOM/DSS-induced CRC . Together, our study identified PLEK2 as a key regulator for the progress of CRC via the regulation of TYMS expression, and demonstrated that PLEK2 is a novel therapeutic target for CRC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1420-9071
1420-682X
1420-9071
DOI:10.1007/s00018-025-05782-x